Non-Canadian reference [Regulatives / Guidelines]

posted by jag009  – NJ, 2013-07-07 01:29 (4736 d 00:03 ago) – Posting: # 10955
Views: 7,323

Hi Helmut!

❝ I have to modify my original response of “no way”. Actually there are some exceptions acceptable. See Canadian Reference Product ❝ Background.

❝ If all applicable criteria are fulfilled, a foreign reference product may be used in a BE study for generic filing.


Personally I think there is too much risk and time involved (what if you submit and they ultimately refuse). I rather spend some cash (for the extra arm) and run a three arm study to compare against references from both countries. This is assuming that you know the reference products from both countries are the same. Helmut, guru, correct me if I am wrong on this example ⇒ Procardia XL (USA) vs Adalat XL (CAN). I think they are the same product.

Note that Canadian ANDA requires potency correction BE analysis as well, US does not (but require potency difference between T and R to be within 5%).

John

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
126 visitors (0 registered, 126 guests [including 22 identified bots]).
Forum time: 01:33 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5